Story thread · 2 reports / 2 sources

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

financialpost.com · 5dShare

August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory milestones Acquisition of Theravance Biopharma, Inc. expected to close in 2H 2026, adding durable commercial cash flows and expanding Zymeworks’ diversified revenue base Continued advancement […]

First report: Zymeworks under pressure as earnings arrive amid acquisition — investing.com, 5d